CHARLES SCHWAB INVESTMENT MANAGEMENT INC - GALECTIN THERAPEUTICS INC ownership

GALECTIN THERAPEUTICS INC's ticker is GALT and the CUSIP is 363225202. A total of 79 filers reported holding GALECTIN THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.74 and the average weighting 0.0%.

Quarter-by-quarter ownership
CHARLES SCHWAB INVESTMENT MANAGEMENT INC ownership history of GALECTIN THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$33,433
+33.3%
17,4130.0%0.00%
Q2 2023$25,075
-31.4%
17,4130.0%0.00%
Q1 2023$36,567
+85.8%
17,4130.0%0.00%
Q4 2022$19,677
-32.1%
17,4130.0%0.00%
Q3 2022$29,000
+26.1%
17,4130.0%0.00%
Q2 2022$23,000
-20.7%
17,4130.0%0.00%
Q1 2022$29,000
-21.6%
17,4130.0%0.00%
Q4 2021$37,000
-45.6%
17,4130.0%0.00%
Q3 2021$68,000
+21.4%
17,4130.0%0.00%
Q2 2021$56,000
-66.9%
17,413
-77.5%
0.00%
Q1 2021$169,000
-12.0%
77,488
-9.4%
0.00%
Q4 2020$192,000
-16.2%
85,5010.0%0.00%
Q3 2020$229,000
-19.6%
85,501
-8.0%
0.00%
Q2 2020$285,000
+56.6%
92,939
+0.5%
0.00%
Q1 2020$182,000
-31.3%
92,4440.0%0.00%
Q4 2019$265,000
-22.1%
92,4440.0%0.00%
Q3 2019$340,000
+9.0%
92,444
+23.1%
0.00%
Q2 2019$312,000
+205.9%
75,092
+250.9%
0.00%
Q1 2018$102,000
+41.7%
21,4000.0%0.00%
Q4 2017$72,000
+56.5%
21,4000.0%0.00%
Q3 2017$46,000
-13.2%
21,4000.0%0.00%
Q2 2017$53,000
-84.9%
21,400
-85.9%
0.00%
Q1 2017$351,000
+294.4%
152,300
+476.9%
0.00%
Q1 2015$89,000
-3.3%
26,4000.0%0.00%
Q4 2014$92,000
-30.8%
26,4000.0%0.00%
Q3 2014$133,000
-63.6%
26,4000.0%0.00%
-100.0%
Q2 2014$365,00026,4000.00%
Other shareholders
GALECTIN THERAPEUTICS INC shareholders Q1 2020
NameSharesValueWeighting ↓
Cutter & CO Brokerage, Inc. 129,488$248,6170.07%
Geneos Wealth Management Inc. 417,350$801,3120.04%
SHEPHERD KAPLAN KROCHUK, LLC 12,000$23,0400.02%
RETIREMENT GUYS FORMULA LLC 11,500$22,0800.02%
Vivaldi Capital Management LP 19,261$36,9810.01%
OSAIC HOLDINGS, INC. 3,275,192$6,288,3450.01%
Traynor Capital Management, Inc. 34,707$66,6380.01%
Atria Wealth Solutions, Inc. 259,800$498,8160.01%
BARRETT & COMPANY, INC. 4,984$9,5690.01%
Wealthspire Advisors, LLC 183,862$353,0160.01%
View complete list of GALECTIN THERAPEUTICS INC shareholders